Relay Therapeutics announced its Q1 2026 financial results and key updates, including FDA granting Breakthrough Therapy designation to its drug zovegalisib for PIK3CA-mutant advanced breast cancer. The company reported promising clinical data showing an 11.1-month median progression-free survival in heavily pre-treated breast cancer patients and plans to start a Phase 3 frontline trial in early 2027. Relay also initiated a Phase 1/2 trial for RLY-8161 targeting NRAS-mutant tumors and expects initial vascular anomalies data in May 2026. With $642 million in cash, the company is well-funded to continue its clinical programs through 2029.
Autonomize, a healthcare AI platform, has strengthened its leadership by appointing three industry veterans to its Advisory Board and hiring Mike Longacre as Head of Transformation. These moves aim to help healthcare organizations move beyond AI pilo...
Fairfax Financial Holdings has finalized its acquisition of Kennedy-Wilson Holdings at $10.90 per share in cash, led by a consortium including Kennedy Wilson's CEO William McMorrow and affiliates of Fairfax. The Kennedy Wilson management team retains...
Aya Gold & Silver Inc., a Canadian precious metals mining company operating in Morocco, will be added to the VanEck Gold Miners ETF (GDX) effective June 19, 2026. This inclusion marks a significant milestone reflecting the company's growth in product...
Nephros, Inc. emphasizes its ultrafiltration technology's ability to capture microplastics and nanoplastics in water, following the U.S. EPA's April 2026 decision to list microplastics as a priority contaminant under the Safe Drinking Water Act. The ...
After the US and Iran reached a deal expected to reopen the Strait of Hormuz, the world's largest tanker owner, Mitsui OSK Lines, cautions that shipping companies will wait for proof the agreement works before resuming normal traffic. The strait is c...
